Javascript must be enabled to continue!
Supportive treatment for cancer – Part 3
View through CrossRef
APPENDIX REPORT 1 -- TABLE OF CONTENTS 1 -- LIST OF FIGURES 5 -- LIST OF TABLES 7 -- APPENDIX I 10 -- 1 SELECTION OF RELEVANT TOPICS BY EXTERNAL EXPERT PANEL 10 -- 1 1 ACCOMPANYING LETTER 10 -- 1 2 TABLE OF POSSIBLE TOPICS AND RESULT OF SELECTION BY EXPERTS 10 -- 1 3 DEFINITIONS OF PALLIATIVE CARE AND TERMINAL CARE 15 -- 2 QUALITY APPRAISAL INSTRUMENTS 16 -- 2 1 AMSTAR 16 -- 2 2 COCHRANE COLLABORATION’S TOOL FOR ASSESSING RISK OF BIAS 18 -- 3 SEARCH SYNTAX BY DATABASE 20 -- 3 1 SYSTEMATIC REVIEWS 20 -- 3 1 1 OVID Medline 20 -- 3 1 2 OVID PreMedline 21 -- 3 1 3 EMBASE 22 -- 3 1 4 Cochrane Library 23 -- 3 2 RANDOMIZED CONTROLLED TRIALS 24 -- 3 2 1 OVID Medline 24 -- 3 2 2 OVID PreMedline 26 -- 3 2 3 EMBASE 27 -- 3 2 4 CENTRAL 27 -- 4 SELECTION PROCESS 29 -- 4 1 RESULTS OF SELECTION PROCESS 29 -- 4 1 1 Guideline websites and websites of organisations in oncology 29 -- 4 2 SPECIFIC SELECTION CRITERIA 30 -- 4 2 1 Bisphosphonates 30 -- 5 MEASUREMENT INSTRUMENTS 33 -- 5 1 PAIN SCALES 33 -- 5 2 ANALGESIC USE MEASUREMENT 44 -- 5 3 PERFORMANCE STATUS SCALES 44 -- 5 4 QUALITY OF LIFE SCALES 46 -- 5 5 SUMMARY TABLE OF SCALES USED IN THIS REPORT 49 -- 6 COMPOSITION OF GUIDELINE DEVELOPMENT GROUP 51 -- 6 1 COMPOSITION OF THE PANEL OF EXTERNAL EXPERTS 51 -- 6 2 COMPOSITION OF THE STAKEHOLDER PANEL 51 -- 6 3 COMPOSITION OF THE KCE EXPERT TEAM 53 -- 6 4 COMPOSITION OF THE SCIENTIFIC VALIDATION TEAM 54 -- APPENDIX II 55 -- 1 QUALITY APPRAISAL 55 -- 1 1 GUIDELINES INCLUDING MULTIPLE TOPICS 55 -- 1 2 NSAIDS AND PARACETAMOL 56 -- 1 3 OPIOIDS 57 -- 1 4 CORTICOSTEROIDS 60 -- 2 GRADE PROFILES BY INTERVENTION AND OUTCOME 61 -- 2 1 NSAIDS AND PARACETAMOL 61 -- 2 2 OPIOIDS 67 -- 2 3 CORTICOSTEROIDS 79 -- 3 FOREST PLOTS 80 -- 3 1 NSAIDS AND PARACETAMOL 80 -- 3 2 OPIOIDS 80 -- 3 3 CORTICOSTEROIDS 80 -- 4 EVIDENCE TABLES 81 -- 4 1 NSAIDS AND PARACETAMOL 81 -- 4 2 OPIOIDS 91 -- 4 3 CORTICOSTEROIDS 144 -- 5 OVERVIEW OF INCLUDED AND EXCLUDED STUDIES 145 -- 5 1 OVERVIEW OF INCLUDED SRS 145 -- 5 2 OVERVIEW OF INCLUDED SRS FOUND BY HANDSEARCH 145 -- 5 3 OVERVIEW OF EXCLUDED SRS 145 -- 5 4 OVERVIEW OF INCLUDED RCTS 145 -- 5 5 OVERVIEW OF EXCLUDED RCTS 146 -- 6 EXAMPLE OF OPIOID EQUIANALGESIC TABLE 147 -- APPENDIX III 148 -- 1 QUALITY APPRAISAL 148 -- 1 1 GUIDELINES INCLUDING MULTIPLE TOPICS 148 -- 1 2 ANTIDEPRESSANTS 149 -- 1 3 ANTICONVULSANTS 151 -- 1 4 RADIOTHERAPY FOR PAINFUL BONE METASTASES 152 -- 1 5 RADIONUCLIDES FOR PAINFUL BONE METASTASES 154 -- 1 6 BISPHOSPHONATES FOR PAINFUL BONE METASTASES 156 -- 1 7 CELIAC PLEXUS BLOCK 158 -- 2 GRADE PROFILES BY INTERVENTION AND OUTCOME 159 -- 2 1 ANTIDEPRESSANTS 159 -- 2 2 ANTICONVULSANTS 170 -- 2 3 RADIOTHERAPY FOR PAINFUL BONE METASTASES 179 -- 2 4 RADIONUCLIDES FOR PAINFUL BONE METASTASES 186 -- 2 5 BISPHOSPHONATES FOR PAINFUL BONE METASTASES 190 -- 2 6 CELIAC PLEXUS BLOCK 208 -- 3 FOREST PLOTS 211 -- 3 1 RADIOTHERAPY FOR PAINFUL BONE METASTASES 211 -- 3 2 RADIONUCLIDES FOR PAINFUL BONE METASTASES 221 -- 3 2 1 Radionuclides versus placebo 221 -- 3 3 BISPHOSPHONATES FOR PAINFUL BONE METASTASES 230 -- 4 EVIDENCE TABLES 234 -- 4 1 ANTIDEPRESSANTS 234 -- 4 2 ANTICONVULSANTS 243 -- 4 3 RADIOTHERAPY FOR PAINFUL BONE METASTASES 264 -- 4 4 RADIONUCLIDES FOR PAINFUL BONE METASTASES 295 -- 4 5 BISPHOSPHANATES FOR PAINFUL BONE METASTASES 301 -- 4 6 CELIAC PLEXUS BLOCK 343 -- 5 OVERVIEW OF INCLUDED AND EXCLUDED STUDIES 351 -- 5 1 OVERVIEW OF INCLUDED SRS 351 -- 5 2 OVERVIEW OF INCLUDED SRS FOUND BY HANDSEARCH 351 -- 5 3 OVERVIEW OF EXCLUDED SRS 352 -- 5 4 OVERVIEW OF INCLUDED RCTS 352 -- 5 5 OVERVIEW OF EXCLUDED RCTS 353 -- APPENDIX IV 354 -- 1 CONSULTATION OF EXPERT PANEL 354 -- 2 CONSULTATION OF STAKEHOLDER PANEL 390 -- REFERENCES 411
Belgian Health Care Knowledge Centre (KCE)
Title: Supportive treatment for cancer – Part 3
Description:
APPENDIX REPORT 1 -- TABLE OF CONTENTS 1 -- LIST OF FIGURES 5 -- LIST OF TABLES 7 -- APPENDIX I 10 -- 1 SELECTION OF RELEVANT TOPICS BY EXTERNAL EXPERT PANEL 10 -- 1 1 ACCOMPANYING LETTER 10 -- 1 2 TABLE OF POSSIBLE TOPICS AND RESULT OF SELECTION BY EXPERTS 10 -- 1 3 DEFINITIONS OF PALLIATIVE CARE AND TERMINAL CARE 15 -- 2 QUALITY APPRAISAL INSTRUMENTS 16 -- 2 1 AMSTAR 16 -- 2 2 COCHRANE COLLABORATION’S TOOL FOR ASSESSING RISK OF BIAS 18 -- 3 SEARCH SYNTAX BY DATABASE 20 -- 3 1 SYSTEMATIC REVIEWS 20 -- 3 1 1 OVID Medline 20 -- 3 1 2 OVID PreMedline 21 -- 3 1 3 EMBASE 22 -- 3 1 4 Cochrane Library 23 -- 3 2 RANDOMIZED CONTROLLED TRIALS 24 -- 3 2 1 OVID Medline 24 -- 3 2 2 OVID PreMedline 26 -- 3 2 3 EMBASE 27 -- 3 2 4 CENTRAL 27 -- 4 SELECTION PROCESS 29 -- 4 1 RESULTS OF SELECTION PROCESS 29 -- 4 1 1 Guideline websites and websites of organisations in oncology 29 -- 4 2 SPECIFIC SELECTION CRITERIA 30 -- 4 2 1 Bisphosphonates 30 -- 5 MEASUREMENT INSTRUMENTS 33 -- 5 1 PAIN SCALES 33 -- 5 2 ANALGESIC USE MEASUREMENT 44 -- 5 3 PERFORMANCE STATUS SCALES 44 -- 5 4 QUALITY OF LIFE SCALES 46 -- 5 5 SUMMARY TABLE OF SCALES USED IN THIS REPORT 49 -- 6 COMPOSITION OF GUIDELINE DEVELOPMENT GROUP 51 -- 6 1 COMPOSITION OF THE PANEL OF EXTERNAL EXPERTS 51 -- 6 2 COMPOSITION OF THE STAKEHOLDER PANEL 51 -- 6 3 COMPOSITION OF THE KCE EXPERT TEAM 53 -- 6 4 COMPOSITION OF THE SCIENTIFIC VALIDATION TEAM 54 -- APPENDIX II 55 -- 1 QUALITY APPRAISAL 55 -- 1 1 GUIDELINES INCLUDING MULTIPLE TOPICS 55 -- 1 2 NSAIDS AND PARACETAMOL 56 -- 1 3 OPIOIDS 57 -- 1 4 CORTICOSTEROIDS 60 -- 2 GRADE PROFILES BY INTERVENTION AND OUTCOME 61 -- 2 1 NSAIDS AND PARACETAMOL 61 -- 2 2 OPIOIDS 67 -- 2 3 CORTICOSTEROIDS 79 -- 3 FOREST PLOTS 80 -- 3 1 NSAIDS AND PARACETAMOL 80 -- 3 2 OPIOIDS 80 -- 3 3 CORTICOSTEROIDS 80 -- 4 EVIDENCE TABLES 81 -- 4 1 NSAIDS AND PARACETAMOL 81 -- 4 2 OPIOIDS 91 -- 4 3 CORTICOSTEROIDS 144 -- 5 OVERVIEW OF INCLUDED AND EXCLUDED STUDIES 145 -- 5 1 OVERVIEW OF INCLUDED SRS 145 -- 5 2 OVERVIEW OF INCLUDED SRS FOUND BY HANDSEARCH 145 -- 5 3 OVERVIEW OF EXCLUDED SRS 145 -- 5 4 OVERVIEW OF INCLUDED RCTS 145 -- 5 5 OVERVIEW OF EXCLUDED RCTS 146 -- 6 EXAMPLE OF OPIOID EQUIANALGESIC TABLE 147 -- APPENDIX III 148 -- 1 QUALITY APPRAISAL 148 -- 1 1 GUIDELINES INCLUDING MULTIPLE TOPICS 148 -- 1 2 ANTIDEPRESSANTS 149 -- 1 3 ANTICONVULSANTS 151 -- 1 4 RADIOTHERAPY FOR PAINFUL BONE METASTASES 152 -- 1 5 RADIONUCLIDES FOR PAINFUL BONE METASTASES 154 -- 1 6 BISPHOSPHONATES FOR PAINFUL BONE METASTASES 156 -- 1 7 CELIAC PLEXUS BLOCK 158 -- 2 GRADE PROFILES BY INTERVENTION AND OUTCOME 159 -- 2 1 ANTIDEPRESSANTS 159 -- 2 2 ANTICONVULSANTS 170 -- 2 3 RADIOTHERAPY FOR PAINFUL BONE METASTASES 179 -- 2 4 RADIONUCLIDES FOR PAINFUL BONE METASTASES 186 -- 2 5 BISPHOSPHONATES FOR PAINFUL BONE METASTASES 190 -- 2 6 CELIAC PLEXUS BLOCK 208 -- 3 FOREST PLOTS 211 -- 3 1 RADIOTHERAPY FOR PAINFUL BONE METASTASES 211 -- 3 2 RADIONUCLIDES FOR PAINFUL BONE METASTASES 221 -- 3 2 1 Radionuclides versus placebo 221 -- 3 3 BISPHOSPHONATES FOR PAINFUL BONE METASTASES 230 -- 4 EVIDENCE TABLES 234 -- 4 1 ANTIDEPRESSANTS 234 -- 4 2 ANTICONVULSANTS 243 -- 4 3 RADIOTHERAPY FOR PAINFUL BONE METASTASES 264 -- 4 4 RADIONUCLIDES FOR PAINFUL BONE METASTASES 295 -- 4 5 BISPHOSPHANATES FOR PAINFUL BONE METASTASES 301 -- 4 6 CELIAC PLEXUS BLOCK 343 -- 5 OVERVIEW OF INCLUDED AND EXCLUDED STUDIES 351 -- 5 1 OVERVIEW OF INCLUDED SRS 351 -- 5 2 OVERVIEW OF INCLUDED SRS FOUND BY HANDSEARCH 351 -- 5 3 OVERVIEW OF EXCLUDED SRS 352 -- 5 4 OVERVIEW OF INCLUDED RCTS 352 -- 5 5 OVERVIEW OF EXCLUDED RCTS 353 -- APPENDIX IV 354 -- 1 CONSULTATION OF EXPERT PANEL 354 -- 2 CONSULTATION OF STAKEHOLDER PANEL 390 -- REFERENCES 411.
Related Results
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Diagnostic Rate of the Cancer by BDORT Utilizing the Cancer Slide
Diagnostic Rate of the Cancer by BDORT Utilizing the Cancer Slide
Purpose:
To make a diagnosis of cancer with BDORT (resonance test), we can choose two methods. One is to use a chemical agent like Integrin α5β1 or Oncogene C-f...
Abstract ED02-04: Intersection of cancer, aging, and survivorship
Abstract ED02-04: Intersection of cancer, aging, and survivorship
Abstract
Cancer is a disease associated with aging, with approximately 60% of cancer diagnoses occurring in patients age 65 and older. Of 10.8 million cancer survivo...
Coexisting Granulomatous Mastitis and Breast Cancer: A Systematic Review
Coexisting Granulomatous Mastitis and Breast Cancer: A Systematic Review
Abstract
Introduction: Granulomatous mastitis (GM) is a rare inflammatory breast disease that mimics carcinoma. GM can coexist with breast cancer (BC), though the relationship rema...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

